Noetik Secures $40M Series A

Noetik, a San Francisco-based AI-native biotech company, has successfully raised $40 million in a Series A funding round. This funding will help accelerate the development of next-generation cancer therapeutics by leveraging advanced machine learning and spatial data technologies.

• Funding Round: Led by Polaris Partners, with additional participation from Khosla Ventures, Wittington Ventures, and Breakout Ventures, along with ongoing support from existing investors like DCVC, Zetta Venture Partners, and others.

• Use of Funds: Noetik plans to scale its spatial omics-based atlas of cancer biology and enhance its in vivo CRISPR Perturb-Map platform. The company is also expanding the training of its OCTO foundation model for cancer research.

• Innovative Platform: Noetik’s platform combines multimodal spatial omics data with high-throughput CRISPR perturbation technology, enabling the discovery of new cancer treatments. These technologies improve the ability to identify potential drug targets and biomarkers, increasing the likelihood of clinical success.

With this significant funding, Noetik is well-positioned to further innovate in the field of cancer therapeutics and make a lasting impact in the fight against cancer.